MX2024010584A - Pclx-001 oral en el tratamiento del cancer humano. - Google Patents

Pclx-001 oral en el tratamiento del cancer humano.

Info

Publication number
MX2024010584A
MX2024010584A MX2024010584A MX2024010584A MX2024010584A MX 2024010584 A MX2024010584 A MX 2024010584A MX 2024010584 A MX2024010584 A MX 2024010584A MX 2024010584 A MX2024010584 A MX 2024010584A MX 2024010584 A MX2024010584 A MX 2024010584A
Authority
MX
Mexico
Prior art keywords
pclx
per day
oral
treatment
human cancer
Prior art date
Application number
MX2024010584A
Other languages
English (en)
Spanish (es)
Inventor
John Robert Mackey
Neal Maynard Davies
Original Assignee
Pacylex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pacylex Pharmaceuticals Inc filed Critical Pacylex Pharmaceuticals Inc
Publication of MX2024010584A publication Critical patent/MX2024010584A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2024010584A 2022-03-03 2023-03-03 Pclx-001 oral en el tratamiento del cancer humano. MX2024010584A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263316153P 2022-03-03 2022-03-03
PCT/CA2023/050281 WO2023164776A1 (en) 2022-03-03 2023-03-03 Oral pclx-001 in the treatment of human cancer

Publications (1)

Publication Number Publication Date
MX2024010584A true MX2024010584A (es) 2024-09-06

Family

ID=87882761

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024010584A MX2024010584A (es) 2022-03-03 2023-03-03 Pclx-001 oral en el tratamiento del cancer humano.

Country Status (10)

Country Link
US (1) US20250161299A1 (cg-RX-API-DMAC7.html)
EP (1) EP4486344A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025507923A (cg-RX-API-DMAC7.html)
KR (1) KR20240155234A (cg-RX-API-DMAC7.html)
CN (1) CN118829428A (cg-RX-API-DMAC7.html)
AU (1) AU2023228703A1 (cg-RX-API-DMAC7.html)
CA (1) CA3244234A1 (cg-RX-API-DMAC7.html)
IL (1) IL314984A (cg-RX-API-DMAC7.html)
MX (1) MX2024010584A (cg-RX-API-DMAC7.html)
WO (1) WO2023164776A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025050208A1 (en) * 2023-09-05 2025-03-13 Pacylex Pharmaceuticals Inc. Oral pclx-001 in the treatment of human cancer
CN120361006A (zh) * 2025-05-19 2025-07-25 上海交通大学医学院附属第九人民医院 Nmt1抑制剂及其在制备实体瘤治疗药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102496892B1 (ko) * 2012-10-30 2023-02-06 페이실렉스 파마슈티컬스 인코포레이티드 암의 합성치사 및 치료
EP3325662B1 (en) * 2015-07-17 2023-08-30 Pacylex Pharmaceuticals Inc. Epigenetic silencing of nmt2
GB201820660D0 (en) * 2018-12-19 2019-01-30 Imperial Innovations Ltd Cancer treatments
MX2023004341A (es) * 2020-10-20 2023-05-24 Pacylex Pharmaceuticals Inc Uso de inhibidores de n-miristoil transferasa (nmt) en el tratamiento del cancer, trastornos autoinmunes y trastornos inflamatorios.

Also Published As

Publication number Publication date
EP4486344A1 (en) 2025-01-08
WO2023164776A1 (en) 2023-09-07
CA3244234A1 (en) 2023-09-07
US20250161299A1 (en) 2025-05-22
KR20240155234A (ko) 2024-10-28
AU2023228703A1 (en) 2024-09-12
JP2025507923A (ja) 2025-03-21
IL314984A (en) 2024-10-01
EP4486344A4 (en) 2026-03-04
CN118829428A (zh) 2024-10-22

Similar Documents

Publication Publication Date Title
EA201301270A1 (ru) Способ комбинированного, направленного к egfr лечения рака
DK1169059T3 (da) Docetaxel i kombination med rhuMAb HER2 til behandling af cancere
MXPA03003960A (es) Combinaciones de farmacos (v.gr., clorpromazina y pentamidina) para el tratamiento de desordenes neoplasticos.
MX2025009943A (es) Derivado de camptotecina, su conjugado, su metodo de preparacion y su uso medico
DK1551409T3 (da) Anvendelse af quinazolinderivatet ZD6474 kombineret med gemcitabin og eventuelt ioniserende stråling ved behandling af cancer
MX2022007371A (es) Tratamiento del hipoparatiroidismo.
PH12021553102A1 (en) Methods of treating fabry disease in patients having renal impairment
CR20200602A (es) Métodos para potenciar la biodisponibilidad y la exposición de un abridor de canales de potasio dependientes de voltaje
MX2023009376A (es) Uso de conjugado de anticuerpo-farmaco dirigido a her2 en el tratamiento de cancer de mama especifico.
MX2023014131A (es) Derivado de 7-nitro-8-hidroxiquinolina, metodo de preparacion y uso medico del mismo.
WO2023046060A8 (zh) 治疗kras突变的癌症患者
CR20220250A (es) Métodos para el tratamiento de trastornos depresivos
WO2004006849A3 (en) Combinations of drugs for the treatment of neoplasms
WO2016181225A3 (en) Methods and compositions for inhibition of egf/egfr pathway in combination with tyrosine kinase inhibitors
JP2009535298A5 (cg-RX-API-DMAC7.html)
US20250205269A1 (en) Anti-tumor agent containing taxane compound, and anti-tumor effect enhancer
WO2000006136A3 (en) Therapeutic combination of polyamine with an anticancer agent
IL314984A (en) Oral PCLX-001 for the treatment of human cancer
MX2012005497A (es) Tivozanib y temsirolimus en combinacion.
EP3127544B1 (en) Anti-tumor drug containing anti-tumor platinum complex, and anti-tumor effect enhancer
RU2474421C1 (ru) Способ профилактики осложнений при лечении больных раком легкого
RU2639463C1 (ru) Способ лечения острого лучевого эзофагита
MX2024010607A (es) Terapia combinada de un inhibidor de pi3k y un inhibidor de pd-1
UA145235U (uk) Спосіб лікування метеорологічного хейліту
MX2026003109A (es) Azd1390, o una sal farmaceuticamente aceptable de esta, en combinacion con radiacion para usarse en un metodo de tratamiento de un tumor del snc